Want to see HK:1477 full AI Analyst Report?
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$4.04 - HK$10.94
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$4.28B
Enterprise ValueHK$5.69K
Total Cash (Recent Filing)HK$547.50M
Total Debt (Recent Filing)HK$187.62M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 28, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe sharp revenue increase indicates stronger commercial traction and product adoption. Sustained growth would improve operating leverage, expand the company’s presence in China’s ophthalmology market, and support future progress toward profitability.
Solid Gross MarginA gross margin near 44% shows that commercialized products retain meaningful economic value after direct costs. Maintaining this level as sales scale could help fund regulatory activity, selling infrastructure, and the transition toward sustainable earnings.
Low Financial LeverageVery low leverage gives Ocumension financial flexibility to continue developing and commercializing ophthalmic therapies without heavy debt-service pressure. The stronger balance sheet can also provide resilience while the company works toward positive cash generation.
Bears Say
Persistent UnprofitabilityDespite narrowing losses, the business has not yet demonstrated sustainable earnings. Continued negative EBIT and EBITDA limit internally funded expansion, weaken returns on equity, and leave profitability dependent on further revenue growth and operating leverage.
Negative Cash GenerationPersistent operating and free-cash-flow deficits show that commercial growth is not yet self-financing. Although cash burn moderated in 2025, continued external funding needs could constrain investment capacity and create dilution or financing risk over time.
Dependence On Licensed AssetsReliance on in-licensed products can accelerate market access but leaves part of the economics and pipeline dependent on external partners. Upfront, milestone, and royalty obligations may limit margins and reduce control over long-term product development.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$4.04 and its highest was HK$10.94 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$4.28B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 28, 2026 which is tomorrow.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 26, 2026. The company reported -HK$0.047 earnings per share for the quarter, beating the consensus estimate of -HK$0.082 by HK$0.035.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Overvalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.047 in its last earnings report, beating expectations of -HK$0.082. Following the earnings report the stock price went down -0.996%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
―
Mabpharm Limited
―
Zhaoke Ophthalmology Ltd.
―
Transcenta Holding Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―